Brendan Bradley – Managing Director – DevEx Resources (ASX:DEV) is an exploration company with a diversified portfolio of high-quality projects spanning some of Australia’s best endowed mining regions.
Copyright 2024 – Finance News Network
Source: Finance News Network
11 Mar 2021 - Rural Funds Group Limited (ASX:RFF) General Manager - Investor Relations and Marketing, James Powell, presents on the group's HY21 results.
Read More13 May 2024 - Lithium Universe's CEO Alex Hanly unveils the company's strides in 2024 towards North American lithium independence.
Read More23 Apr 2021 - Capral Limited (ASX:CAA) Managing Director Tony Dragicevich talks about the company's strong FY20 results despite COVID, its product mix, operating environment and outlook.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More26 Nov 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Read More09 Dec 2020 - Alterity Therapeutics Limited (ASX:ATH) Chairman and CEO Geoffrey Kempler provides an update on the company's lead compound ATH434 for Multiple System Atrophy, its dual strategy in Europe and the US and its Phase 2 plans.
Read More25 Jul 2024 - Stuart Crow - Non Executive Chairman - Lake Resources N.L. (ASX:LKE, OTC: LLKKF) is a responsible lithium developer utilising state of-the-art ion exchange extraction technology for production of sustainable, high purity lithium from its flagship Kachi Project in Catamarca Province within the Lithium Triangle in Argentina. Lake also has three additional early-stage projects in this region.
Read More03 Dec 2019 - Noxopharm Limited (ASX:NOX) Executive Chairman & CEO, Dr Graham Kelly, discusses clinical results from the company's Phase 1b clinical DARRT-1 trial for its lead product candidate, Veyonda, with low-dose radiotherapy.
Read More01 Jul 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results from the company's study of its NYX-PCSK9i cholesterol-lowering compound.
Read More26 Aug 2025 - Technical breakthroughts, customer traction and the road ahead
Read More
